Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized vehicle-controlled study of topical ocular SAF312 in healthy Japanese participants
jRCT2031210588Phase 1Completed
- Sponsor
- Novartis
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SAF312 in chronic pain (9 arms), sponsored by Novartis. Primary endpoints: Systemic and ocular safety and tolerability, Ocular safety and 1 more. Started Feb 2022; status: completed.
02
Drugs
SAF312
03
Conditions
chronic pain
Beyond the preview
Go deeper on jRCT2031210588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210588.